293 related articles for article (PubMed ID: 31114181)
1. Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials.
Li C; Cheng W; Guo J; Guan W
Int J Chron Obstruct Pulmon Dis; 2019; 14():799-808. PubMed ID: 31114181
[No Abstract] [Full Text] [Related]
2. Correlation of Inhaled Long-Acting Bronchodilators With Adverse Cardiovascular Outcomes in Patients With Stable COPD: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Wu J; Ye Y; Li C; Zhou W; Chang R
J Cardiovasc Pharmacol; 2019 Sep; 74(3):255-265. PubMed ID: 31306366
[TBL] [Abstract][Full Text] [Related]
3. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
Rodrigo GJ; Price D; Anzueto A; Singh D; Altman P; Bader G; Patalano F; Fogel R; Kostikas K
Int J Chron Obstruct Pulmon Dis; 2017; 12():907-922. PubMed ID: 28360514
[TBL] [Abstract][Full Text] [Related]
4. Comparative Cardiovascular and Cerebrovascular Safety of Inhaled Long-Acting Bronchodilators in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.
Dong YH; Chang CH; Gagne JJ; Hsu CL; Lai MS
Pharmacotherapy; 2016 Jan; 36(1):26-37. PubMed ID: 26799347
[TBL] [Abstract][Full Text] [Related]
5. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
Hizawa N
Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.
Kardos P; Worsley S; Singh D; Román-Rodríguez M; Newby DE; Müllerová H
Int J Chron Obstruct Pulmon Dis; 2016; 11():2885-2895. PubMed ID: 27932872
[TBL] [Abstract][Full Text] [Related]
7. Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis.
Xia N; Wang H; Nie X
PLoS One; 2015; 10(9):e0137904. PubMed ID: 26378450
[TBL] [Abstract][Full Text] [Related]
8. An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD.
Singh D; D'Urzo AD; Donohue JF; Kerwin EM; Molins E; Chuecos F; Ribera A; Jarreta D
Int J Chron Obstruct Pulmon Dis; 2019; 14():2835-2848. PubMed ID: 31827323
[TBL] [Abstract][Full Text] [Related]
9. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis.
Rogliani P; Matera MG; Ora J; Cazzola M; Calzetta L
Int J Chron Obstruct Pulmon Dis; 2017; 12():3469-3485. PubMed ID: 29255354
[TBL] [Abstract][Full Text] [Related]
10. Inhaled treatment of COPD: a Delphi consensus statement.
Ninane V; Corhay JL; Germonpré P; Janssens W; Joos GF; Liistro G; Vincken W; Gurdain S; Vanvlasselaer E; Lehouck A
Int J Chron Obstruct Pulmon Dis; 2017; 12():793-801. PubMed ID: 28293106
[TBL] [Abstract][Full Text] [Related]
11. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials.
Lai CC; Chen CH; Lin CYH; Wang CY; Wang YH
Int J Chron Obstruct Pulmon Dis; 2019; 14():1539-1548. PubMed ID: 31371939
[TBL] [Abstract][Full Text] [Related]
12. Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review.
Lopez-Campos JL; Calero-Acuña C; Márquez-Martín E; Quintana Gallego E; Carrasco-Hernández L; Abad Arranz M; Ortega Ruiz F
Int J Chron Obstruct Pulmon Dis; 2017; 12():1867-1876. PubMed ID: 28694697
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy.
Dhungana S; Criner GJ
Int J Chron Obstruct Pulmon Dis; 2017; 12():2307-2312. PubMed ID: 28814858
[TBL] [Abstract][Full Text] [Related]
14. Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study.
Wang MT; Liou JT; Lin CW; Tsai CL; Wang YH; Hsu YJ; Lai JH
JAMA Intern Med; 2018 Feb; 178(2):229-238. PubMed ID: 29297057
[TBL] [Abstract][Full Text] [Related]
15. Aclidinium bromide and formoterol fumarate for the maintenance treatment of chronic obstructive pulmonary disease.
Haley R; Gupta N; Sethi S
Expert Rev Clin Pharmacol; 2020 Feb; 13(2):103-113. PubMed ID: 31951778
[No Abstract] [Full Text] [Related]
16. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
Singh D; Corradi M; Spinola M; Papi A; Usmani OS; Scuri M; Petruzzelli S; Vestbo J
Int J Chron Obstruct Pulmon Dis; 2017; 12():2917-2928. PubMed ID: 29062229
[TBL] [Abstract][Full Text] [Related]
17. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
Petite SE
Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
[TBL] [Abstract][Full Text] [Related]
18. Long-Acting Bronchodilator Initiation in COPD and the Risk of Adverse Cardiopulmonary Events: A Population-Based Comparative Safety Study.
Suissa S; Dell'Aniello S; Ernst P
Chest; 2017 Jan; 151(1):60-67. PubMed ID: 27554300
[TBL] [Abstract][Full Text] [Related]
19. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease.
Buhl R; Magder S; Bothner U; Tetzlaff K; Voß F; Loaiza L; Vogelmeier CF; McGarvey L
Respir Med; 2017 Jan; 122():58-66. PubMed ID: 27993292
[TBL] [Abstract][Full Text] [Related]
20. The safety of dual bronchodilation on cardiovascular serious adverse events in COPD.
Rogliani P; Ora J; Matera MG; Cazzola M; Calzetta L
Expert Opin Drug Saf; 2018 Jun; 17(6):589-596. PubMed ID: 29716427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
